Comparison 4. Three infusions of natalizumab (300 mg) versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to induce remission at 10 weeks	1	905	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.81, 1.01]
2 Failure to induce remission at 12 weeks	2	1414	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.78, 0.92]
3 Failure to induce clinical response at 10 weeks	1	905	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.72, 1.00]
4 Failure to induce clinical response at 12 weeks	2	1414	Risk Ratio (M‐H, Fixed, 95% CI)	0.76 [0.67, 0.86]
5 Change in CDAI from baseline to 12 weeks	1	507	Mean Difference (IV, Fixed, 95% CI)	‐49.60 [‐67.35, ‐31.85]
6 Adverse events up to week 12	2	1415	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.98, 1.08]
7 Withdrawal due to adverse event	2	1415	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.59, 1.26]
8 Serious adverse events	2	1414	Risk Ratio (M‐H, Random, 95% CI)	0.76 [0.37, 1.56]
9 Failure to induce remission at 10 weeks (post hoc subgroup analyses)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
9.1 Patients with elevated CRP at baseline	1	660	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.73, 0.94]
9.2 Concurrent use of immunosuppressants	1	300	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.67, 0.96]
9.3 Previous use of anti‐TNF therapy	1	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.73, 0.98]
10 Failure to induce remission at 12 weeks (post hoc subgroup analyses)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
10.1 Patients with elevated CRP at baseline	1	660	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.71, 0.92]
10.2 Concurrent use of immunosuppressants	1	300	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.65, 0.96]
10.3 Previous use of anti‐TNF therapy	1	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.73, 0.98]
11 Failure to induce clinical response at 10 weeks (post hoc subgroup analyses)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.1 Patients with elevated CRP at baseline	1	660	Risk Ratio (M‐H, Fixed, 95% CI)	0.76 [0.63, 0.91]
11.2 Concurrent use of immunosuppressants	1	300	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.51, 0.89]
11.3 Previous use of anti‐TNF therapy	1	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.68 [0.55, 0.84]
12 Failure to induce clinical response at 12 weeks (post hoc subgroup analyses)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
12.1 Patients with elevated CRP at baseline	1	660	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.58, 0.86]
12.2 Concurrent use of immunosuppressants	1	300	Risk Ratio (M‐H, Fixed, 95% CI)	0.68 [0.51, 0.91]
12.3 Previous use of anti‐TNF therapy	1	358	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.53, 0.83]